DNA and RNA of over 2,000 genes from major molecular pathways of a patient’s tumor are analyzed. The Oncobox:Integral Test algorithm is applied to distinguish which molecular targets are the most crucial, and the patient’s oncologist receives a report with drug options ranked by expected effectiveness.
Here are the steps in more detail:
Step 1: Tumor specimen is sent to Oncobox. For the analysis, we need a slice of a formalin-fixed paraffin-embedded (FFPE) block of a tumor biopsy or fragment of a tumor removed after surgery. The FFPE blocks are normally kept in the hospitals where the biopsy or surgery procedures were perfomed.
Step 2: Based on the tumor data, Oncobox:Integral Test analyzes DNA and RNA signatures of over 2,000 genes that are included in major tumor molecular pathways. Expression of individual molecular targets is analyzed, along with activation of intracellular pathways.
Step 3: Basing on its unique knowledge dabase, Oncobox:Integral Test simulates the effect of over 140 target drugs on the patient’s cancer.
Step 4: Drugs are ranked on possible effectiveness, and a report is sent to the patient’s oncologist to assist with treatment decisions.
Benefits of Oncobox:Integral test
The following drug types are comprised:
The research underlying the Oncobox:Integral Test is available in Our Research section.
We are also developing companion diagnostics for several drugs currently on the market to help doctors decide if one specific drug they may be considering is right for their patient. One example is the Oncobox:Sorafenib test, which can help doctors determine if the drug Nexavar (Sorafenib) may be effective for patients with cancers of the kidney, liver, and thyroid.
Tumor types eligible for Oncobox tests
Sample test report for Lung cancer
Some details have been removed from the sample reports to protect patient confidentiality.
ORDER ONCOBOX FOR YOUR PATIENT